Critical Comparison: Orion OYJ (ORINY) and Its Rivals

Orion OYJ (OTCMKTS:ORINY) is one of 245 public companies in the “MED – DRUGS” industry, but how does it contrast to its rivals? We will compare Orion OYJ to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.

Dividends

Orion OYJ pays an annual dividend of $0.32 per share and has a dividend yield of 0.8%. Orion OYJ pays out 24.4% of its earnings in the form of a dividend. As a group, “MED – DRUGS” companies pay a dividend yield of 1.5% and pay out 38.8% of their earnings in the form of a dividend.

Risk & Volatility

Orion OYJ has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Orion OYJ’s rivals have a beta of 0.57, indicating that their average stock price is 43% less volatile than the S&P 500.

Institutional & Insider Ownership

44.0% of shares of all “MED – DRUGS” companies are owned by institutional investors. 13.7% of shares of all “MED – DRUGS” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Orion OYJ and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion OYJ	0	1	0	0	2.00
Orion OYJ Competitors	1237	3400	9193	333	2.61

As a group, “MED – DRUGS” companies have a potential upside of 141.02%. Given Orion OYJ’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Orion OYJ has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Orion OYJ and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orion OYJ	$1.67 billion	$356.98 million	29.68
Orion OYJ Competitors	$1.08 billion	$57.59 million	-5.50

Orion OYJ has higher revenue and earnings than its rivals. Orion OYJ is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Orion OYJ and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion OYJ	21.74%	36.23%	21.28%
Orion OYJ Competitors	-20,305.47%	-74.68%	-24.21%

Summary

Orion OYJ rivals beat Orion OYJ on 8 of the 15 factors compared.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.